

PTO/SB/17 (12-04v2)
Approved for use through 07/31/2005. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Effe	ctive on 12/08/2	2004.				nplete if Kr	plays a valid OMB control num nown
Fees pursuant to the Consol				Application Numb	ber 10/	666,301	
PEE IP	CNA	MITTA		Filing Date	09/	19/2003	
Fo	or FY 2	005		First Named Inve		RTLEY, Am	nanda April
Applicant claims sma	ill ontity etatus	Sec. 37 CER 1 27		Examiner Name PEFFLEY, Michael			
			[/	Àrt Unit	373	39 [:]	
TOTAL AMOUNT OF PA	YMENT (\$) 230	[7	Attorney Docket I	No. 123	61-15US	
METHOD OF PAYMEN	NT (check al	I that apply)					
Check Credit	Card 1	Money Order	None	Other (5k	case identify	n:	
		it Number: 195113					RENAULT LLP
		account, the Director					VERMOET CEL
	s) indicated be						except for the filing fee
Charge any	additional fee	(s) or underpayments	s of fee(s	A []	any overpa		Souther to me initial the
	R 1.16 and 1.	.17		. La Oredit e			Samuel Sand Sand
nformation and authorization	n on PTO-2038	Come public, crean co	370 (100)	TRUOT SHOULD INC.	De Incidoe	on this form	i. Provide creat card
FEE CALCULATION	:						
I. BASIC FILING, SEA			ES				
	FILING	FEES S				TION FEE	
Application Type	Fee (\$)		ee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fees Paid (\$)
Utility	300		500	250	200	100	
Design	200		100	50	130	65	
Plant	200		300	150	160	80	
Reissue	300		500	250	600	300	
Provisional	200	100	Ö-	0	0	0	
2. EXCESS CLAIM FE		ैंस.	•	, U	=	•	Small Entity
Fee Description						Fee (\$)	Fee (\$)
Each claim over 20 (50	25.
Each independent cla		including Keissues	i)			200	100
Multiple dependent of Total Claims	claims Extra Clain	e_4 /e	main D	19 A 2857		360	180
46 - 20 or HP =		ns <u>Fee (\$)</u> × 50 =	Fee P	ald (\$)			Dependent Claims
HP = highest number of total						Fee (\$)	Fee Paid (\$)
Indep. Claims	Extra Clain		Fee Pa	aid (\$)			
-3 or HP =		x=		······			
HP = highest number of inde		paid for, if greater than	3.				
. APPLICATION SIZE If the specification and		exceed 100 sheets c	of naner	(excluding ele	ectronical	ly filed sea	uence or computer
							or each additional 50
sheets or fraction t	hereof. See	35 U.S.C. 41(a)(1)	VG) and	d 37 CFR 1.16	(s).		Or caon admiration
Total Sheets	Extra Shee	ets Number of	f each a	additional 50 or round up to a wh	fraction th	ereof Fe	ee (\$) Fee Paid (\$)
- 100.=	-	/50 =	<u>"</u> "	OUTO UP to a will	ole numbe	r) × ,	
l. OTHER FEE(S) Non-English Specifi	ication, \$1	30 fee (no small er	itity dis	count)			Fees Paid (\$
Other (e.g., late filin	g surchapge): Submission of Info	ormation	Disclosure State	ement		180
JBMITTED BY	12						
gnature	VL		Reg	gistration No. 349	963	Telept	none: 416.216.3903
me (Print/Tyne) Paul I El			I (Att	omey/Agent)			lune 27 - 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering; preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Baylis Medical Company Inc.

Attorney Docket: 12361-15US

Serial No.: 10/666,301

Group Art Unit: 3739

Filed: September 19, 2003

Examiner: Michael Peffley

For:

SURGICAL PERFORATION DEVICE WITH CURVE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 CFR 1.56, Applicant hereby submits a Supplemental Information Disclosure Statement on Form PTO/SB/08A and SB/08B (2 sheets). Copies of the non-U.S. patent references and non-patent references are enclosed.

Applicant reserves the right to contest the applicability of the enclosed as prior art against the subject application.

This Supplemental Information Disclosure Statement is being filed subsequent to the issuance of a first office action, and therefore fees of official \$180 are submitted herewith on the attached fee transmittal sheet. However, the Commissioner is authorized to charge any deficiencies or overpayment to Deposit Account No. 195113.

Respectfully submitted,

06/28/2005 MBEYENE1 00000073 195113

02 FC:1806

180.00 DA

Paul J Field

Registration No. 34963 **OGILVY RENAULT LLP**

Telephone 416-216-3903 Fax 416-216-3930 pfield@ogilvyrenault.com Suite 3800, P.O. Box 84 Royal Bank Plaza, South Tower 200 Bay Street Toronto, Ontario Canada M5J 2Z4

Date: June 27, 2005



Substitute for form 1449/PTO

Sheet 1

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 3

Examiner Initials*	No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number-Kind Code ^{2 (# Incomp}		<u>'</u>	Figures Appear
		^{US-} 5,683,366	11-04-1997	Eggers et al.	
		^{US-} 5,904,679	05-18-1999	Clayman	
		US- 6,814,733	11-09-2004	Schwartz et al.	
		^{US-} 5,364,393	11-15-1994	Auth et al.	
		^{US-} 5,098,431	03-24-1992	Rydell	
		^{US-} 4,682,596	07-28-1987	Bales et al.	
.,		^{US-} 6,293,945	09-25-2001	Parins et al.	
		^{US-} 4,936,281	06-26-1990	Stasz	
-		^{US-} 4,928,693	05-29-1990	Goodin et al.	
		^{US-} 6,296,615	10-02-2001	Brockway et al.	
		^{US-} 5,403,338	04-04-1995	Milo	
		^{US-} 6,650,923	11-18-2003	Lesh et al.	
		^{US-} 5,921,957	07-13-1999	Killion et al.	
		^{US-} 3,448,739	06-10-1969	Stark et al.	
		us- 5,281,216	01-25-1994	Klicek	
		^{US-} 6,811,544	11-02-2004	Schaer	
		US- 2002/0123749	09-05-2002	Jain	· · · · · · · · · · · · · · · · · · ·
		US-2002/0169377	11-14-2002	Khairkhahan et al.	
		US-			

		FORE	IGN PATENT DOCL	JMENTS	·	-
Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Г	
		Country Code ³ "Number ⁴ "Kind Code ³ (if known)	MM-DD-YYYY	-	Or Relevant Figures Appear	۲۵
		EP-0315730	05-15-1989	Osypka		
		WO-9320747	10-28-1993	Rosar		
						L
						┝
		,		<u> </u>		_

	·			
Examiner Signature		,	Data Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precode the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiatry is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the CHef Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Reserved Reduction Act of 1005 me non

	te for form 1449/PTO			`	Complete if Known
				Application Number	10/666,301
-			CLOSURE	Filing Date	09/19/2003
STATEMENT BY APPLICANT				First Named Inventor	Amanda April HARTLEY
	(Use as many she	ote se n	acaseanil	Art Unit	3739
(control many strate as messagely)				Examiner Name	Michael Peffley
Sheet	2	of.	3	Attorney Docket Number	12361-15US

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS	
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1.	CA PEDRA, LN DE SOUSA, SR PEDRA, WP FERREIRA, SL BRAGA, CA ESTEVES, MV SANTANT, JE SOUSA, VF FONTES: "New Percutaneous techniques for perforating the pulmonary valve in pulmonary atresia with Intact ventricular septum". Arg Bras Carlol. 77(5):471-48 (2001).	
	2	DG NYKANEN, J PHIKALA, GP TAYLOR, LN BENSON. "Radiofrequency assisted perforation of the atrial septum in a swine model: feasibility, biophysical and histological characteristics". Circulation. 100(Suppl 1):I-804 (1999).	
•	3	Baylis Medical Company Inc. 'Radio Frequency Perforation System". (2001).	
	4	"ABSTRACT of European Patent No. 0315730 to Osypka". (1989).	
	5	Boston Scientific Corporation. "http://www.bostonscientific.com/med_specialty/deviceDetail.jsp?task=tskBasicDevice.jsp§ionId=4&relId=1, 20,21,22&deviceId=488&uniqueId=MPDB58". Explorer ST Cahteters. 2 pages. (Date or printing - June, 2005)	
	6	Boston Scientific Corporation. "http://www.bostonscientific.com/med_specialty/devlceDetail.jsp?task=tskBasicDevice.jsp§ionid=4&relld=2,74,75,76 &deviceId=556&uniqueId=MPDB4320". Impulse Angiographic Catheter. 2 pages. (Date of printing:- June, 2005)	
	7	Boston Scientific Corporation. "http://www.bostonscientific.com/med_specialty/deviceDetail.jsp?task=tskBasicDevice.jsp§ionId=4&relId=2, 74,75,76&deviceId=11026&uniqueId=MPDB2799". PT2 Guide Wire. 2 pages. (Date of printing - June, 2005)	
	8 .	IntraLuminal Therapeutics, Inc. "http://www.intraluminal.com/products/catheter.html". Safe Cross Support Catheter. 1 page. (Date of printing - June, 2005)	
	9	Lake Region Manufacturing, Inc. "http://www.lakergn.com/jmc.htm". Paragon Güldewire. 2 pages. (Date of printing - June, 2005)	
	10	Medtronic Inc. "http://www.medtronic.com/epsystems/diagnostic_catheters.html". Diagnostic Catheters. 7 pages. (Date of printing - April, 2005)	- West

Examiner	Daté .	
Signature	Considered	

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to epplicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sont to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known
	Application Number	10/666,301
INFORMATION DISCLOSURE	Filing Date	09/19/2003
STATEMENT BY APPLICANT	First Named Inventor	Amanda April HARTLEY
(Use as many sheets as necessary)	Art Unit	3739
(Use as many should as nacessary)	Examiner Name	Michael Peffley
Sheet 3 of 3	Attorney Docket Number	12361-15US

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	.No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	11	Johnson & Johnson Geteway, LLC. Tittp://www.injgateway.com/home.jhtml?loc=USENG&page=viewContent&contentId=fc0de00100001435&nodekey=/Prod_Info/ Specialty/Arrytyhmia_Management/Electrophysiology/EP_Diagnostic_Catheters*. EP Diagnostic Catheters. 2 pages. (Date of printing - June, 2005)	
-	12	Johnson & Johnson Gateway, LLC. http://www.inigateway.com/home.jhtml;jsessionid=JNSF/TWOADICOCQPCCECPJYKB2ilWNSC7icc=USENG&page=viewContent&contentUd=fcOde00100000524&nodekey=/Prod_Info/Specially/Cardiovascular_and_Thoracic/Cardiac_Diagnosis_Interve_ntions/Diagnositic_Wines&_requestid=228805*;_Diagnositic_Guldewires_4_pages_i/Date of printing - June_2005)	
	13	H JUSTINO. LN BENSON, DG NYKANEN. "Transcatheter Creation of an Atrial Septal Defect Using Radiofrequency Perforation". Catheter Cardiovasc Interv. 54(1):83-87 (September, 2001).	
	14	N.SHIMKO, P. SAVARD, K.SHAH. "Radio frequency perforation of cardiac tissue: modelling and experimental results". Med. Biol. Eng. Comput. 38:575-582 (2000).	
· - · · · · · · · · · · · · · · · · · ·	.15	T ABDEL-MASSIH, Y BOUDJEMLINE, P BONHOEFFER. "Unusual interventional management in an adult with tetralogy of Fallot". Cardiol Young. 13(2):203-205 (April, 2003).	
•	16	T HUMPL, B SODERBERG, BW MCCRINDLE, DG NYKANEN, RM FREEDOM, WG WILLIAMS, LN BENSON. Percutaneous balloon valvotomy in pulmonary atresta with intact ventricular septum: impact on patient care'. Circulation. 108(7):826-832 (August, 2003)	
,	17	CA PEDRA, RM FILHO, RS ARRIETA, R TELLEZ; VF FONTES. "Recanalization of a discrete atretic right pulmonary artery segment with a new radiofrequency system". Catheter Cardiovasc Interv. 60(1):82-87 (September, 2003)	
H	18	HW KORT, DT BALZER. *Radiofrequency perforation in the treatment of acquired left pulmonary atresia following repair of tetraligy of Failot*. Catheter Cardiovasc Interv. 60(1):79-81 (September, 2003)	
	19	G VELDTMAN, A PEIRONE, LN BENSON. "Radiofrequency perforation of the atrial septum: Preliminary experimental evaluation and development." PICS VII Abstracts. Catheter Cardiovasc Interv. 60(1):132 (September, 2003)	
	20	F.GODART, C.FRANCART, GM.BREVIERE, C.REY. "Pulmonary vavulotomy with the Nykanen radiofrequency guide in pulmonary stresia with intact interventricular septum". Arch Mai Coeur Valss. 96(5):517-520 (May, 2003). 'Article is in French with an English summary.	

Examiner Signature	:	ż	Date Considered		
*EYAMINED: 1	itial if reference considered whether as a set	siteties is in a series with AIDED con		4 44	

^{**}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the inclindual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.